Evidence map›Paper›PMID 39065550›Full record

ArticlePharmaceutics2024

Cyclodextrins and Amino Acids Enhance Solubility and Tolerability of Retinoic Acid/Tretinoin: Molecular Docking, Physicochemical, Cytotoxicity, Scratch Assay, and Topical Gel Formulations Investigation.

Zeinab Fathalla, Mai E Shoman, Hebatallah S Barakat, Adel Al Fatease, Ali H Alamri, Hamdy Abdelkader

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Complexes of Fat-Soluble Vitamins with Cyclodextrins.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zeinab FathallaDepartment of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Mai E ShomanDepartment of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.ORCID 0000-0001-6837-5093
Hebatallah S BarakatDepartment of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria 21525, Egypt.
Adel Al FateaseDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62223, Saudi Arabia.ORCID 0000-0002-4608-5949
Ali H AlamriDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62223, Saudi Arabia.ORCID 0000-0001-6790-2226
Hamdy AbdelkaderDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62223, Saudi Arabia.ORCID 0000-0003-4989-5143

Funding

the Deanship of Research and Graduate Studies RGP 1/42/45
6 · The paper itself

Abstract

With increasing longevity globally, the search for effective and patient-friendly anti-aging solutions has been growing. Retinoic acid (Ret) is an FDA-approved anti-aging and anti-wrinkling formula, however, its poor solubility and poor tolerability hamper its use in cosmetically accepted formulations. In this study, cyclodextrins and arginine were investigated for improving the solubility and tolerability of retinoic acid through the formation of inclusion complexes and salt formation, respectively. Two different methods were employed: physical mixing and kneading. The prepared dispersions were investigated for molecular docking (MD), solubility, thermal and spectral analyses, cytotoxicity, and scratch assays. The optimized disperse systems were formulated in a gel formulation and characterized for rheological, in vitro release, and kinetics. The MD, DSC, and FTIR results indicated that both β- and hydroxy propyl (HP) β-cyclodextrins could host RA in their cavities and form inclusion complexes. Ret can form a salt with the basic amino acid arginine. Solubility studies of RA significantly (

Indexed as

agingcyclodextrinscytotoxicitygelsl-arginineretinoic acidscratch assay

Identifiers

PMID39065550
PMCPMC11280329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.